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Rationale: Current guidelines suggest that asthma should be controlled with the lowest dose of
maintenance medication required.
Objectives: To evaluate the effects of a low dose of inhaled corticosteroid compared to
a placebo, on airway inflammation and responsiveness in patients with mild symptomatic
asthma.
Methods: In this randomized double-blind, placebo-controlled, parallel group study, we looked
at the influence of inhaled fluticasone propionate 250 mg/day for 3 months followed by 100 mg/
day for 9 months on airway inflammation and methacholine responsiveness in non-smoking
subjects with mild allergic asthma. Subjects were evaluated at baseline and 3, 6, 9 and 12
months after treatments; a 2-week evaluation of respiratory symptoms and peak expiratory
flow measurements was done before each visit.
Results: Fifty-seven subjects completed the 3-month study period. Airway responsiveness, ex-
pressed as the PC20 methacholine, increased by 0.27 and 1.14 doubling concentrations,onsiveness; ATS, American Thoracic Society; ECRHS, European Community Respiratory Health Survey;
ced expiratory volume in one second; FEV1/FVC, ratio of forced expiratory volume in one second/
propionate; P, placebo; PC20, provocative concentration inducing a 20% fall in FEV1; PEF, peak
ening.
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Benefits of a minimal dose of ICS in mild controlled asthma 1555respectively, in placebo-treated (nZ 33) and in fluticasone-treated (nZ 24) asthmatic
subjects (pZ 0.03). An additional improvement in PC20 up to 2.16 doubling concentrations
was observed in the fluticasone-treated group during the 9-month lower-dose treatment
(pZ 0.0004, end of low-dose period compared with placebo). Sputum eosinophil counts
decreased after 3 months of fluticasone 250 mg/day compared with placebo (p< 0.0001) and
remained in the normal range during the 9-month lower-dose treatment. Respiratory symp-
toms and peak expiratory flows did not change significantly throughout the study in both
groups.
Conclusion: In mild asthma, keeping a regular minimal dose of ICS after asthma control has
been achieved, may lead to a further reduction in airway responsiveness and keep sputum
eosinophil count within the normal range.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Inhaled corticosteroids (ICS) are widely used to treat
asthma.1 In mild asthma, fluticasone, at a dose of 1000 mg/
day, reduced methacholine responsiveness by slightly less
than 2 doubling concentrations over a period of 2 months
and significantly reduced airway inflammation.2 In mild to
moderate asthma, low ICS doses also have significant
effects on these parameters; a 14-week treatment with
fluticasone propionate, 200 mg/day, reduced methacholine
responsiveness by 1.86 doubling doses and eliminated the
eosinophilic airway inflammation assessed by induced
sputum analysis.3 Previous studies suggested that subjects
with mild asthma who are at high risk of asthma exacer-
bations could particularly benefit from early ICS treat-
ment.4e11 ICS provided better asthma control than
bronchodilators alone in patients with mild asthma not
considered to need maintenance treatment.2,4,12 Ideally,
the minimum dose of ICS necessary to maintain asthma
control should be used to minimize side effects.5,7,8,13e17
Based on the fact that mild asthma is often undertreated
and that regular ICS help eliminate airway inflammation
and possibly prevent the progression of asthma, the OPTIMA
and the START studies evaluated low-dose ICS in mild
persistent asthma and showed a reduction of asthma
exacerbations after, respectively, one year of treatment
with BUD 200 mg/day and 3 years with budesonide 400 mg/
day.4,6,12,18e21 In another study by Boushey et al., a regular
one-year treatment with budesonide 400 mg/day had
a similar effect on asthma control, frequency of exacer-
bations and quality of life as an intermittent treatment22
although the methodology of this study was criticized.8
The use of continuous low-dose ICS in mild or mild
intermittent asthma was recently evaluated in two studies
comparing the effects of fluticasone propionate (FP) at
a daily dose of 250 mg, respectively during 11 and 6 months,
and resulted in an improvement lung function and airway
hyperresponsiveness (AHR) and a reduction of asthma
exacerbations.23,24 However, in one of these studies, 34% of
patients were already using ICS before randomisation.23 In
another study, a dose of FP 100 mg twice daily and a daily
dose of combined salmeterol 50 mg and FP 100 mg improved
similarly peak expiratory flows in ICS-naı¨ve patients with
mild asthma albeit FP 100 mg twice daily was better in
reducing exacerbations rates.25As few studies analyzed the effect of a prolonged
treatment with a low dose of ICS on airway responsiveness
(AHR) and inflammation in mild asthma, the objective of
this study was to evaluate in patients with clinically
controlled mild steroid-naı¨ve asthma previously treated
with a short-acting b2-agonist only whether a low dose of
inhaled corticosteroids (100 mg/day during 9 months),
which is the lowest dose of the GINA low-dose category,
would maintain the improvement in airway inflammation
and airway responsiveness obtained after a short-course of
low-dose inhaled corticosteroids (3-month course of FP
250 mg/day) in subjects with mild asthma.26Methods
Study design: multicentric double-blind placebo-controlled
randomized study comparing fluticasone propionate (FP)
250 mg/day followed by a 9-month maintenance treatment
of FP 100 mg/day to placebo in mild steroid-naı¨ve asthmatic
subjects.
Subjects
Subjects aged 18e45 years were recruited from Asthma and
Respiratory Allergy clinics of participating institutions and
from advertisements in local media.
Inclusion criteria included: mild stable asthma with
intermittent asthma symptoms (less than twice a week in
the last 3 months); a provocative concentration of meth-
acholine inducing a 20% fall in forced expiratory volume in
one second (PC20 FEV1) between 0.5 and 16 mg/mL,
a FEV1> 70% predicted, current exposure to a relevant
indoor allergen, no respiratory infection within 6 weeks of
the beginning of the study and use of a short-acting b2-
agonist alone (less than 3 times per week). Patients with
a PC20 between 8 and 16 mg/mL had a known history of
asthma with previously measured PC20< 8 mg/mL. All
patients were enrolled out of the pollen season to minimize
seasonal allergic exposure at entry in the study.
Exclusion criteria included lifetime previous use of any
bronchial anti-inflammatory agents; uncontrolled asthma,
smoking history >10 packs-years, smoking in the last twelve
months and pregnancy, breastfeeding or inadequate
contraception.
1556 L.-P. Boulet et al.Study protocol
On baseline evaluation (visits 1e2), subjects completed the
ECRHS respiratory questionnaire27 and had an allergy skin-
prick test. A methacholine inhalation test and induced
sputum analysis were done twice at a two-week interval.
Means of both evaluations were considered as baseline
values. Subjects were then randomly assigned by a collab-
orator not implicated in the study to receive either the
placebo during one year or a 3-month course of fluticasone
propionate (FP) 250 mg/day followed by a 9-month main-
tenance treatment of FP 100 mg/day. A subject number was
provided to preserve the blinding during the study so that
neither the subjects nor the investigators were aware of
the treatment group assignment. Treatments were taken
blindly with a metered-dose inhaler at 18 2 h. Compliance
to therapy was monitored by questionnaire and by checking
Diskus counters. Subjects came to the laboratory every 3
months during treatment (visits 3e6) for a methacholine
inhalation test and induced sputum analysis. They were
questioned on asthma exacerbations (periods of increased
asthma symptoms with an increased use or need to use
asthma medication) in the period preceding study visits.
During the study, they received no corticosteroid treatment
except the study medication. Rescue bronchodilators
(short-acting b2-agonist) could be taken on demand. No
other asthma medication was allowed.
Symptoms scores and peak expiratory flow (PEF) were
measured during 2 weeks at baseline evaluation and every
three months during treatment periods.
The primary outcome variable was methacholine airway
responsiveness. Secondary outcome variables were airway
inflammation measured by induced sputum, respiratory
symptoms, peak expiratory flows and asthma exacerbations.
The study was approved by the institutional Ethics
Committee and all subjects gave written informed
consent.Study tests
Atopy was confirmed by skin-prick tests with 16 common
allergens including household animals, pollens; house dust
and house dust mites, moulds and cockroach. Spirometry
was done according to current ATS standards using 3
reproducible measurements of FEV1. Methacholine chal-
lenges were done at the same time of day, in the morning,
according to a standard method described by Hargreave
et al.28 using a calibrated spirometer satisfying ATS
recommendations.29,30 At first visit, the rating of the
perception of bronchoconstriction-induced symptoms was
determined on a modified Borg Scale (0e10) during the
methacholine inhalation test before each FEV1 measure-
ment.30,31 Sputum was induced with hypertonic saline by
the method described by Pin et al.32 and modified by Piz-
zichini et al.33
Symptoms of cough, shortness of breath, chest tight-
ness, wheeze and phlegm production were evaluated daily
during 2 weeks before each visit on a scale from 0 to 5,
where 0Z no symptoms, 1Zminimal, 2Z light, 3Zmo-
derate, 4Z severe, and 5Z very severe symptoms.
Patients noted all scores on a diary card and the mean dailysymptoms score was obtained. Peak expiratory flows were
measured morning and evening in triplicate, using a mini-
Wright device (Allen & Hanburys, Glaxo, Toronto, Montreal)
and the best result was kept.
Statistical analysis
Results are expressed as mean SD or as otherwise
specified.
No formal power calculation was performed. According
to a study by Inman et al.,34 we anticipated that a number
of 12 subjects per group should be sufficient to observe
significant changes in airway responsiveness with 90%
power. Regarding airway inflammation, Bettiol et al.35
showed that a sample size of 11 subjects per group had
a 70% power to detect a 50% reduction in sputum eosinophil
counts.
From subjects’ characteristics data, one-way ANOVA and
Fisher’s exact test were used to analyze continuous and
categorical variables respectively. All cell count variables
as well as PC20 were log-transformed to stabilize variance.
Variables expressed in percentage were analyzed using the
sin1 (O) transformation.36 Statistical results from these
parameters were expressed with transformed values. To
compare groups at baseline and at 3 months, a three-way
ANOVA was used to analyze data. One factor (fixed) was
associated to the comparison among the groups of subjects
(placebo or FP). One factor was linked to the subjects’
effect (random nested effect). The third factor (fixed) was
associated to the comparison between visits (at baseline
and 3 months). This factor was analyzed as repeated
measurements. An interaction effect between the fixed
factors was added to the statistical model. A compound
symmetric structure (with a constant variance and constant
covariance) was used as covariance matrix. The same
statistical approach was used to compare groups over the
time course (3, 6, 9 and 12 months) using a homogeneous
first-order autoregressive structure for repeated measure-
ments and using their associated baseline value as cova-
riate. All variables were analyzed using the appropriate
transformation (log and sin1 (O) transformations). Statis-
tical results from these parameters were expressed with
transformed values. Results of representative measures
between 3 and 12 months were expressed using the back
transformation with the 95% confidence intervals from
least-square means adjusted for baseline values. The
univariate normality assumption was verified with the
ShapiroeWilk test and the Brown and Forsythe’s variation
of Levene’s test statistic was used to verify the homoge-
neity of variances. Multivariate normality was verified with
Mardia tests. All assumptions were fulfilled. The results
were considered significant with p-values <0.05. The data
were analyzed using the statistical package program SAS
v9.1.3 (SAS Institute Inc., Cary, NC).
Results
Sixty-nine subjects were enrolled into the study; 34 were
randomized in the placebo group and 35 in the treatment
group. One subject was excluded in the placebo group
because of an exacerbation of asthma which required
Benefits of a minimal dose of ICS in mild controlled asthma 1557treatment with inhaled corticosteroids; there were no
other asthma exacerbations throughout the study. The
study patient flow is summarized in Fig. 1.
Baseline measures of PC20, FEV1, FVC and induced
sputum parameters
On entry in the study, AHR to methacholine ranged from
0.83 to 16 mg/mL (mean: 4.1 mg/mL) and mean baseline
FEV1 was 99.2 12.4% of predicted values for all subjects.
Subjects’ baseline characteristics for the placebo- and FP-
treated groups are summarized in Table 1. Mean baseline %
predicted FEV1 (pZ 0.82), FVC (pZ 0.16) and PC20 were
similar in both groups. Mean baseline ratios for FEV1/FVC
were respectively, 82.3 7.4% and 84.2 6.2% in the
placebo- and the FP-treated groups (p< 0.0001). Borg
scores (mean SD) at PC20 for perception of methacholine-
induced respiratory symptoms were not significantly
different in subjects from the placebo or FP groups for
breathlessness (2.0 1.7 and 1.9 1.2, respectively), chest
tightness (1.9 1.0 and 2.4 1.8), wheeze (0.7 1.033 completed Visit 3
1 discontinuation due to asthma
exacerbation
34 allocated to placebo
106 patient
69 rando
24 completed Visit 4
 9 lost to follow-up
22 completed Visit 5
 2 lost to follow-up
18 completed Visit 6
4 lost to follow-up
Follow
Visit
Follow
Visit
Follow
Visit
Follow
Visit
Continued allocation
to placebo
Figure 1 Studyand1.1 1.4), phlegm production (0.9 1.2 and 0.5 0.8)
or cough (1.2 1.1 and 1.0 1.0) (p> 0.05).
At baseline, means of induced sputum total number of
cells  106 of the placebo (0.295, 95% confidence interval
(CI): 0.184e0.470) and FP groups (0.382, 0.228e0.637)
were similar (pZ 0.12). Cell differentials were not signifi-
cantly different between groups for macrophages:
(respectively 69, 95% CI: 61e76 and 65, 55e73) pZ 0.24,
eosinophils: (1.3, 0.2e3.2 and 1.7, 1.0e2.5) pZ 0.62,
neutrophils: (26, 17e34 and 28, 20e38) pZ 0.57, lympho-
cytes: (1.5, 0.6e2.7 and 0.9, 0.2e2.0) pZ 0.44 and bron-
chial cells: (1.4, 0.7e2.4 and 1.9, 0.9e3.2) pZ 0.92.
Baseline measures of symptoms and PEF
Asthma symptoms measured during the weeks before
treatments were similar in the placebo and FP groups with
respective average scores of 0.4 0.6 and 0.3 0.5 per day
(p> 0.05) corresponding tominimal symptoms. Mean AM/PM
PEF were respectively 412 82/423 84 L/min in the
placebo group and 484 73/489 73 L/min in the FP group,37 not randomized:
24 not meeting inclusion criteria
7 refused to participate
6 other reasons
24  completed Visit 3
 1  non compliance to treatment
10  lost to follow-up
35 allocated to fluticasone
propionate 250µg/day
s enrolled
mized
20 completed Visit 4
 4 lost to follow-up
16 completed Visit 5
4 lost to follow-up
13 completed Visit 6
3 lost to follow-up
-Up
 3
-Up
 4
-Up
 5
-Up
 6
Allocation to fluticasone
propionate 100µg/day
patient flow.
Table 1 Subjects’ characteristics.
Mild asthma
Placebo
group(nZ 33)
FPa group
(nZ 24)
Gender M/F 10M/23F 11M/13F
Age (years) Mean SD 27 7 26 8
Atopy (n)
Indoor allergens 33 24
Outdoor allergens 28 19
Smoking status (n)
Non-smoker 28 18
Ex-smokerb 5 6
FEV1 (L) Mean SD 3.33 0.62 3.55 0.62
% predicted 98.5 12.5 97.2 10.5
FVC (L) Mean SD 4.09 0.83 4.17 0.77
% predicted 101.6 12.3 97.1 11.6
Ratio FEV1/FVC SD (%) 82.3 7.4 84.2 6.2
PC20 (mg/mL)
(Geometric mean
of baseline visits)
3.2 3.9
a FP: Fluticasone propionate.
b Ex-smoker: Smoking history <10 pack-years and no smoking
in the last year.
1558 L.-P. Boulet et al.corresponding to 81%/82% and 88%/92% of predicted values
(pZ 0.006 between groups).
Expiratory flows and methacholine responsiveness
during treatments
During treatment and maintenance periods, FEV1 increased
progressively up to a 6% improvement from baseline at the
end of the study in the FP group while it fluctuated in the
group placebo and increased only by 1% (Fig. 2, pZ 0.054
between both groups). Baseline forced vital capacity didFigure 2 Percent change in FEV1 before and after treatment
(dark shade background) and maintenance treatment (light
shade background) for subjects who received placebo (blank
circle) or FP (dark circle). Bars represent sem. Compared with
baseline FEV1 at the end of maintenance treatment improved
by 6% in the FP group and 1% in the placebo group. *pZ 0.054.not change significantly in any group before and after the
treatment period (data not shown). FEV1/FVC ratios did not
vary significantly compared to baseline (both groups:
p> 0.05) during and after treatment (Table 2).
In the placebo group, AHR did not change from baseline to
the 3-month visit with respective mean PC20 values of 3.2
and 4.2 mg/mL (Table 2). Mean PC20 decreased slightly at 6-
and 9-month visits to 2.6 mg/mL and increased to 3.8 mg/ml
after the 12-month visit (pZ 0.04 between visits at 6, 9 and
12 months). The final PC20 was not significantly different
from the baseline value (p> 0.05). In the FP group, PC20
increased from 3.9 mg/mL at baseline to 7.9 mg/mL after
the 3-month visit (p< 0.0001). It kept on increasing during
the maintenance period up to 14.5 mg/mL at the 12-month
visit (pZ 0.27). Consequently, the FP group final PC20 was
higher than the one observed at baseline and also higher
than the final PC20 of the placebo group (pZ 0.0004).
When the variations in AHR were expressed in change in
doubling PC20 values,
37 the FP-treated group and the
placebo group improved by 1.14 and 0.27 doubling
concentrations respectively, at the 3-month visit (pZ 0.03,
Fig. 3). During the maintenance treatment, in the placebo
group, PC20 fluctuated by around 0.5 doubling concentra-
tions from baseline (p> 0.05) while in the FP group, it went
up by 2.16 doubling concentrations compared to baseline
value, providing an additional improvement of more than
one doubling concentration during the maintenance period
compared with the end of the 250 mg/day treatment
period.Airway inflammation during treatments
Total number of cells in induced sputum was unchanged
after the 3-, 6-, 9- and 12-month visits in both groups and
remained similar between groups (data not shown,
pZ 0.39). At the 3-month visit, the mean percentage of
eosinophils decreased from 1.3% to 0.3% (pZ 0.0002) in the
FP group while it did not significantly change in the placebo
group: 1.7e1.8% (p> 0.05, Fig. 4). At the 6-, 9- and
12-month visits, there were no significant differences
compared with baseline sputum eosinophils within groups
(p> 0.05). However, at the 6- and 9-month visits, mean
eosinophil counts were significantly lower in the FP group
compared with the placebo group (both pZ 0.02). At the
12-month visit, all subjects were out of pollen season and
eosinophil counts were low in both groups (p> 0.05).
Symptoms and PEF after treatments
Compared with baseline, respiratory symptoms did not
change significantly in the placebo (0.5 0.7) and the FP
(0.3 0.2) groups after the first treatment (p> 0.05) and
the maintenance treatment (p> 0.05; placebo: 0.3 0.6,
0.3 0.6 and 0.2 0.2 respectively; FP: 0.3 0.3, 0.4 0.4
and 0.1 0.2).
Mean AM/PM PEF (% of predicted values) were not
significantly different from baseline (p> 0.05) in both the
placebo and FP groups, after first treatment (Placebo: 83/
81 respectively and FP: 89%/88%) and the 6-, 9- and 12-
month visits (Placebo: 83/83, 85/83, 88/86 and FP: 90/93,
90/90, 92/90).
Table 2 Adjusted meansa and 95% CI for PC20 methacholine, FEV1, FEV1/FVC and sputum eosinophils.
Placebo group FPb group
PC20
(mg/mL)
FEV1
(% predicted)
Ratio
FEV1/FVC (%)
Sputum
eosinophils (%)
PC20
(mg/mL)
FEV1
(% predicted)
Ratio
FEV1/FVC (%)
Sputum
eosinophils (%)
Baseline 3.2
(2.7e5.6)
98.5
(94.2e102.8)
82.3
(79.8e84.8)
1.7
(1.1e2.5)
3.9
(2.7e5.6)
97.2
(92.7e101.6)
84.2
(82.0e86.3)
1.3
(0.2e3.2)
Visit 3
3 months
post-treatment
4.2
(2.9e6.0)
101.2
(98.6e103.7)
83.6
(82.5e84.8)
1.8
(0.9e3.0)
7.9
(5.2e12.2)
102.9
(99.8e105.9)
85.0
(83.7e86.3)
0.3
(0e1.0)
Visit 4
6 months
post-treatment
2.6
(1.7e3.8)
98.8
(95.9e101.6)
83.0
(81.8e84.3)
2.8
(1.4e4.6)
10.9
(6.9e17.1)
103.1
(99.8e106.2)
85.1
(83.6e86.5)
0.7
(0.1e1.7)
Visit 5
9 months
post-treatment
2.6
(1.7e3.9)
99.6
(96.5e102.7)
82.9
(81.6e84.3)
3.5
(2.0e5.5)
11.1
(6.8e18.3)
104.3
(100.7e107.8)
85.9
(84.3e87.4)
0.8
(0.1e1.9)
Visit 6
12 months
post-treatment
3.8
(2.4e6.0)
100.1
(96.8e103.5)
83.4
(82.0e84.9)
1.6
(0.5e3.2)
14.5
(8.4e25.1)
104.8
(100.8e108.7)
85.5
(83.8e87.2)
0.5
(0e1.6)
a Means adjusted for baseline values.
b Fluticasone propionate.
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Figure 3 Mean changes (sem) in doubling concentrations of
methacholine after treatment (dark shade background), and
during maintenance treatment (light shade background) in the
placebo (blank circle) and the FP (dark circle) groups. The
improvement in number of doubling concentrations was
significant in the FP group after treatment (pZ 0.006).
Compared with placebo at each visit: *pZ 0.03, **p< 0.0001,
ypZ 0.0004.
1560 L.-P. Boulet et al.Discussion
Initiating ICS treatment with a high dose, then reducing to
the minimum (step-down) has been suggested in asthma
although treatment may also be initiated with a low dose
then increased if asthma is still uncontrolled.3,7,38,39 This
study showed that a minimal dose of 100 mg/day of FP,Figure 4 Adjusted mean sputum eosinophil counts (95% CI)
before and after treatment (dark shade background), and
maintenance treatment (light shade background) in the
placebo- (blank circle) and the FP-treated (dark circle) groups.
Treatment with FP reduced sputum eosinophils compared with
baseline (p< 0.0001). Compared with placebo at each visit:
*pZ 0.0002, **pZ 0.02. Measures from 3 to 12 months
adjusted for baseline values.maintained the significant improvement in AHR and
reduction in airway inflammation obtained after a 3-month
treatment with a low dose of 250 mg/day of FP in mild
asthma. After 9 months of maintenance treatment with this
minimal dose, airway responsiveness and FEV1 were still
improved compared to the placebo group and sputum
eosinophils remained in the normal range.
The fact that FEV1 and FVC were in the normal range at
baseline may explain the small change in lung function
after ICS and lack of statistical significance compared to
other studies.40,41 Patients’ asthma symptoms scores and
PEF measures following FP low-dose treatment and main-
tenance period remained similar to baseline. The possibility
that symptoms were present but not recognized is very
unlikely since our patients were good perceivers as
confirmed by a perception score of light to moderate
symptoms for a 20% decrease in FEV1 on the first meth-
acholine test.42 The fact that our patients had mild asthma,
few symptoms and normal baseline PEF may explain this
apparent lack of effect of treatment on these parameters.
In subjects with moderate asthma, doses of 50 and 200 mg/
day of FP were efficient to improve FEV1, AM PEF and
reduce asthma symptoms.40,43 A dose of budesonide
equivalent to 125 mg/day of FP also improved lung function
and reduced symptoms and risks of severe exacerbations in
corticosteroid-naı¨ve patients with moderate asthma.4
Adjustments of therapy with ICS by relying on measures
of AHR or by assessing sputum eosinophils help to maintain
adequate asthma control, especially in reducing the risks of
asthma exacerbation.44e46 However, a controversy exists
whether to maintain or stop low-dose ICS when patients
with mild persistent asthma become asymptoma-
tic.8,15,18,47e49 In patients taking ICS, current guidelines,
recommend regular therapy with ICS in keeping with the
OPTIMA and the START trials while Boushey et al. suggested
a similar effect of intermittent use of ICS together with an
action plan to control asthma exacerbations.4,6,12,15,22
However, a transient improvement in airway responsiveness
and reduction in airway inflammation after short-term
treatment with ICS followed by a loss of these benefits over
the next few weeks after cessation of treatment has been
often observed in subjects with mild to moderate
asthma.3,4,39,44,45,50,51
Another recent study in which corticosteroid-naı¨ve
patients with asymptomatic airway hyperresponsiveness
received a high dose of fluticasone for 6 weeks, showed
that the beneficial effects of the treatment on airway
responsiveness were no longer evident two weeks after
cessation of the ICS.52 In this last study, subjects did not
reach a plateau of improvement of airway responsiveness
and it is unknown if a treatment prolonged over the 6-week
period would have provided further benefits. The loss of
beneficial effect after cessation of treatment is also true
for sputum eosinophil counts, their increase being
a predictor of loss of asthma control and risk of exacerba-
tions.3,38,51,53 As long-term use of low doses of ICS has
minimal adverse effects on child growth and on bone
mineral density in adults, this could be considered a safe
and effective treatment strategy for both populations.54e56
Our study further documents the benefits of pursuing
a minimal dose of ICS to maintain the improvement
obtained with a low dose of ICS in mild asthma.
Benefits of a minimal dose of ICS in mild controlled asthma 1561In these patients, the reduction of sputum eosinophils
and their maintenance within the normal range may reduce
the risks of clinical exacerbations3,57e61 and possibly the
risk of airway remodelling.62 Regular maintenance treat-
ment has been shown to be beneficial in patients with mild
persistent asthma.25 This is supported by the demonstration
that a 3-year treatment with 400 mg/day of budesonide
improved asthma control and reduced asthma exacerba-
tions in adults not previously using regular glucocorticos-
teroids.12 As a dose of 250 mg/day of FP followed by
a maintenance dose of 100 mg/day of FP was efficient to
improve and maintain sputum eosinophils in the normal
range and to improve significantly airway responsiveness in
patients with mild asthma, we suggest that, in these
patients, especially those with a high risk of aggravating
their asthma, a prolonged treatment with ICS, at a low dose
(the lowest currently recommended in guidelines) is
a valuable asthma preventative treatment, minimizing
airway hyperresponsiveness and keeping induced sputum
eosinophils within the normal range in most patients.Conflict of interest and financial disclosure
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